Neurological Disorders: An Overview of Brain and Nervous System Diseases

Neurodegenerative Diseases

Neurodegenerative diseases involve the progressive loss of neurons in specific brain regions, producing gradual decline in cognitive, motor, or behavioral function. Alzheimer disease, the most common neurodegenerative condition, affects approximately 50 million people worldwide and is characterized by the accumulation of amyloid-beta plaques and tau protein tangles that disrupt synaptic function and trigger neuronal death, beginning in the hippocampus and medial temporal lobe before spreading to association cortices. Early symptoms include difficulty forming new memories, followed by progressive decline in language, reasoning, and eventually basic self-care abilities.

Parkinson disease results from the degeneration of dopamine-producing neurons in the substantia nigra, producing the characteristic motor symptoms of resting tremor, rigidity, bradykinesia, and postural instability. The disease also involves non-motor symptoms including depression, sleep disturbances, and cognitive decline that reflect the spread of pathological alpha-synuclein protein aggregates through the brain. Amyotrophic lateral sclerosis (ALS) selectively destroys upper and lower motor neurons, causing progressive paralysis while typically preserving cognitive function. Huntington disease, caused by an expanded CAG repeat in the huntingtin gene, produces involuntary movements, psychiatric symptoms, and cognitive decline through the degeneration of striatal neurons in the basal ganglia.

Cerebrovascular Disorders

Stroke is the sudden interruption of blood flow to a region of the brain, producing rapid neuronal damage and neurological deficits that correspond to the affected area. Ischemic stroke, which accounts for approximately 85 percent of all strokes, occurs when a blood clot blocks a cerebral artery, depriving downstream tissue of oxygen and glucose. Without treatment, neurons in the ischemic core die within minutes, while a surrounding region of partially compromised tissue called the penumbra can be salvaged if blood flow is restored quickly through clot-dissolving medication (thrombolysis) or mechanical clot removal (thrombectomy).

Hemorrhagic stroke occurs when a blood vessel in the brain ruptures, releasing blood into the surrounding tissue and causing damage through both direct compression and toxic effects of blood breakdown products. Subarachnoid hemorrhage, typically caused by rupture of a cerebral aneurysm, produces sudden severe headache and can cause devastating brain damage. Cerebral small vessel disease, a chronic condition affecting the tiny arteries and capillaries of the brain, contributes to cognitive decline, white matter damage, and increased stroke risk, particularly in the elderly and in people with hypertension and diabetes.

Epilepsy and Seizure Disorders

Epilepsy is a neurological condition characterized by recurrent seizures resulting from abnormally synchronized electrical activity in the brain. Seizures can be focal, beginning in a specific brain region, or generalized, involving both hemispheres from the onset. The mechanisms underlying seizure generation involve an imbalance between excitatory and inhibitory neurotransmission, with excessive glutamatergic excitation and insufficient GABAergic inhibition allowing abnormal electrical discharges to spread through neural networks.

Anti-seizure medications work by enhancing inhibitory neurotransmission, reducing excitatory neurotransmission, or stabilizing neuronal membranes to prevent abnormal firing. Approximately one-third of epilepsy patients do not achieve adequate seizure control with medication and may be candidates for surgical removal of the seizure focus, vagus nerve stimulation, or responsive neurostimulation devices that detect abnormal electrical activity and deliver targeted stimulation to interrupt seizures before they develop fully.

Demyelinating Diseases

Demyelinating diseases damage the myelin sheath that insulates neuronal axons, disrupting the rapid saltatory conduction that enables efficient neural communication. Multiple sclerosis (MS) is the most common demyelinating disease, affecting approximately 2.8 million people worldwide. In MS, the immune system mistakenly attacks oligodendrocytes and their myelin in the central nervous system, producing plaques of demyelination scattered throughout the brain and spinal cord. Symptoms vary widely depending on which pathways are affected and can include visual disturbances, muscle weakness, numbness, fatigue, cognitive impairment, and balance difficulties.

MS typically follows one of several disease courses. Relapsing-remitting MS, the most common form, involves episodes of new or worsening symptoms followed by periods of partial or complete recovery. Secondary progressive MS develops in some patients after years of relapsing-remitting disease, with steadily worsening disability between relapses. Disease-modifying therapies that suppress or modulate the immune system can reduce the frequency and severity of relapses and slow the accumulation of disability, but no cure currently exists. Other demyelinating conditions include neuromyelitis optica, which primarily affects the optic nerves and spinal cord, and acute disseminated encephalomyelitis, which can follow viral infections or vaccinations.

Traumatic Brain Injury

Traumatic brain injury (TBI) results from external mechanical force applied to the head, ranging from mild concussion to severe injury with prolonged unconsciousness. The primary injury, the direct mechanical damage at the moment of impact, can include contusion of brain tissue, shearing of axons from rotational forces (diffuse axonal injury), and intracranial hemorrhage. Secondary injury processes that develop over hours to days after the initial trauma include brain swelling, inflammation, excitotoxicity from excessive glutamate release, and oxidative stress, which can significantly worsen the outcome beyond the initial damage.

Mild TBI, commonly called concussion, produces temporary disruption of brain function without visible structural damage on standard imaging. Symptoms including headache, confusion, memory difficulty, and sensitivity to light and noise typically resolve within days to weeks, but a subset of patients experience persistent post-concussion symptoms. Repeated mild TBIs, as experienced by contact sport athletes and military personnel, can produce chronic traumatic encephalopathy (CTE), a progressive neurodegenerative condition characterized by accumulation of abnormal tau protein, mood and behavioral changes, and eventually cognitive decline.

Psychiatric Disorders and the Brain

While traditionally classified separately from neurological disorders, psychiatric conditions including depression, schizophrenia, bipolar disorder, and anxiety disorders are increasingly understood as disorders of brain circuit function. Major depressive disorder involves dysregulation of mood circuits connecting the prefrontal cortex, anterior cingulate cortex, amygdala, and hippocampus, along with alterations in serotonin, norepinephrine, and glutamate neurotransmission. Schizophrenia involves disrupted connectivity between prefrontal and temporal cortices, excessive dopamine signaling in mesolimbic pathways, and widespread white matter abnormalities that impair the coordinated network activity necessary for normal perception, thought, and behavior.

The distinction between neurological and psychiatric disorders is increasingly recognized as artificial, as both involve measurable changes in brain structure, function, and chemistry. Advances in neuroimaging, genetics, and molecular neuroscience are revealing shared mechanisms across traditionally separate diagnostic categories and opening new avenues for treatment that target the underlying neural circuit dysfunction rather than symptom categories alone. This convergence of neurology and psychiatry represents one of the most significant conceptual shifts in modern brain science.

Neuroinflammation Across Disorders

A common thread across many neurological disorders is neuroinflammation, the activation of the brain's resident immune cells, microglia, and the recruitment of peripheral immune factors across a compromised blood-brain barrier. In neurodegenerative diseases, chronic microglial activation produces inflammatory cytokines and reactive oxygen species that damage neurons and accelerate disease progression. In traumatic brain injury, the inflammatory response that helps clear damaged tissue can also cause secondary damage to surviving neurons if it persists beyond the acute phase.

The recognition of neuroinflammation as a shared mechanism across neurological conditions has generated intense interest in anti-inflammatory approaches to treatment. Modulating microglial activation states, enhancing the resolution of inflammation, and restoring blood-brain barrier integrity are active areas of therapeutic research. The emerging understanding that the immune system and nervous system interact continuously, rather than operating independently, represents a fundamental shift in how neurological disease is conceptualized and may lead to novel treatments that address inflammatory drivers of neuronal damage across multiple diagnostic categories. Clinical trials targeting neuroinflammatory pathways are currently underway for conditions ranging from Alzheimer disease to multiple sclerosis to traumatic brain injury, reflecting the growing recognition that controlling inflammation may be as important as addressing the primary disease mechanism.